中国生化药物杂志
中國生化藥物雜誌
중국생화약물잡지
CHINESE JOURNAL OF BIOCHEMICAL PHARMACEUTICS
2015年
7期
104-106
,共3页
TSH抑制疗法%老年甲状腺癌%sIL-2R%CD44V6%TSGF%T淋巴细胞亚群
TSH抑製療法%老年甲狀腺癌%sIL-2R%CD44V6%TSGF%T淋巴細胞亞群
TSH억제요법%노년갑상선암%sIL-2R%CD44V6%TSGF%T림파세포아군
TSH suppression therapy%elderly thyroid cancer%SIL-2R%CD44V6%TSGF%T lymphocyte subsets
目的:探讨促甲状腺激素( thyroid stimulating hormone,TSH)抑制疗法对老年甲状腺癌患者血清可溶性白细胞介素-2受体(soluble interleukin-2 receptor,sIL-2R)、白细胞分化抗原44变异型6(CD44V6)、肿瘤特异性生长因子(tumors pecific growth factor , TSGF)及外周血T淋巴细胞亚群( peripheral blood T lymphocyte subsets,PBTLS)影响。方法收集的本院收治的老年甲状腺癌患者50例,随机分为对照组和实验组,每组各25例,实验组术后给予TSH抑制疗法,对照组术后给予甲状腺素替代疗法,治疗1个月后,对所有患者的血清sIL-2R、CD44V6、TSGF及外周血T淋巴细胞亚群情况进行检测。结果治疗后,与对照组比较,①实验组患者血清sIL-2R水平较低,差异具有统计学意义(P<0.05);②实验组患者的血清CD44V6水平较低(P<0.05);③实验组患者的血清TSGF水平较低(P<0.05);④实验组患者外周血CD3+、CD4+水平较高,CD8+水平较低(P<0.05)。结论 TSH抑制疗法能够降低老年甲状腺癌患者血清sIL-2R、CD44V6、TSGF及淋巴细胞CD8+水平,使外周血T淋巴细胞CD3+、CD4+水平升高,改善患者免疫功能,对临床有指导意义。
目的:探討促甲狀腺激素( thyroid stimulating hormone,TSH)抑製療法對老年甲狀腺癌患者血清可溶性白細胞介素-2受體(soluble interleukin-2 receptor,sIL-2R)、白細胞分化抗原44變異型6(CD44V6)、腫瘤特異性生長因子(tumors pecific growth factor , TSGF)及外週血T淋巴細胞亞群( peripheral blood T lymphocyte subsets,PBTLS)影響。方法收集的本院收治的老年甲狀腺癌患者50例,隨機分為對照組和實驗組,每組各25例,實驗組術後給予TSH抑製療法,對照組術後給予甲狀腺素替代療法,治療1箇月後,對所有患者的血清sIL-2R、CD44V6、TSGF及外週血T淋巴細胞亞群情況進行檢測。結果治療後,與對照組比較,①實驗組患者血清sIL-2R水平較低,差異具有統計學意義(P<0.05);②實驗組患者的血清CD44V6水平較低(P<0.05);③實驗組患者的血清TSGF水平較低(P<0.05);④實驗組患者外週血CD3+、CD4+水平較高,CD8+水平較低(P<0.05)。結論 TSH抑製療法能夠降低老年甲狀腺癌患者血清sIL-2R、CD44V6、TSGF及淋巴細胞CD8+水平,使外週血T淋巴細胞CD3+、CD4+水平升高,改善患者免疫功能,對臨床有指導意義。
목적:탐토촉갑상선격소( thyroid stimulating hormone,TSH)억제요법대노년갑상선암환자혈청가용성백세포개소-2수체(soluble interleukin-2 receptor,sIL-2R)、백세포분화항원44변이형6(CD44V6)、종류특이성생장인자(tumors pecific growth factor , TSGF)급외주혈T림파세포아군( peripheral blood T lymphocyte subsets,PBTLS)영향。방법수집적본원수치적노년갑상선암환자50례,수궤분위대조조화실험조,매조각25례,실험조술후급여TSH억제요법,대조조술후급여갑상선소체대요법,치료1개월후,대소유환자적혈청sIL-2R、CD44V6、TSGF급외주혈T림파세포아군정황진행검측。결과치료후,여대조조비교,①실험조환자혈청sIL-2R수평교저,차이구유통계학의의(P<0.05);②실험조환자적혈청CD44V6수평교저(P<0.05);③실험조환자적혈청TSGF수평교저(P<0.05);④실험조환자외주혈CD3+、CD4+수평교고,CD8+수평교저(P<0.05)。결론 TSH억제요법능구강저노년갑상선암환자혈청sIL-2R、CD44V6、TSGF급림파세포CD8+수평,사외주혈T림파세포CD3+、CD4+수평승고,개선환자면역공능,대림상유지도의의。
Objective To analyze the effect of TSH inhibition on soluble interleukin 2 receptor ( sIL-2R), interleukin 44 variant 6 (CD44V6), tumor specific growth factor (TSGF) and T lymphocyte subsets in elderly patients with thyroid cancer.Methods 50 elderly patients with thyroid cancer in our hospital were collected.The patients were randomly assigned to experimental and control groups, 25 cases in each group, patients in the experimental group were given TSH suppression therapy after surgery , patients in control group were given thyroxine replacement therapy after operation, treatment for 1 month, serum SIL-2R, CD44v6, TSGF and peripheral blood T lymphocyte subsets situation were detected in all patients with .ResuIts After treatment, compared with the control group, ①in the experimental group, the level of serum sIL-2R was significantly lower, the difference was statistically significant(P<0.05);②the serum CD44V6 level was lower in the experimental group (P<0.05);③the serum TSGF level was lower in the experimental group (P<0.05);③in the experimental group,the levels of CD3 + and CD4 +were higher, levels of CD8 + were lower ( P<0.05 ) .ConcIusions TSH suppression therapy can reduce senile thyroid cancer patients serum SIL-2R, CD44v6, TSGF and CD8 +lymphocyte level, peripheral blood T lymphocyte CD3 +, CD4 +levels were elevated,and improve the immune function of patients , the clinical has guiding significance .